Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Se Ik Kim

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Frontiers in Oncology|June 1, 2022
Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian CancerWenyu Wang, Untack Cho, Anna Yoo, et al.
Gynecologic Oncology|January 21, 2024
Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trialSe Ik Kim, Je-Gun Joung, Yoo-Na Kim, et al.
BMJ Open|July 6, 2026
Impact of fertility preservation on quality of life, recurrence and reproductive success in young female cancer survivors: a Korean prospective multicentre cohort study protocol (LIFE-Repro)Hyun-Woong Cho, Se Ik Kim, Jeong-Yeol Park, et al.
The Journal of Obstetrics and Gynaecology Research|December 10, 2019
Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter studySe Ik Kim, Chel Hun Choi, Kidong Kim, et al.
Gynecologic Oncology|January 11, 2026
Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/ SHAPE trialSe Ik Kim, Jae-Weon Kim, Janice S Kwon, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapyAngelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, et al.
Cancers|August 7, 2021
Cancer Patients' Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in KoreaJune Young Chun, Se Ik Kim, Eun Young Park, et al.
Journal of Gynecologic Oncology|February 8, 2024
Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancerSeung-Hyuk Shim, Jung-Yun Lee, Yoo-Young Lee, et al.
Cancers|July 24, 2021
Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian CancerChae Young Han, David A Patten, Se Ik Kim, et al.
The Lancet. Oncology|August 30, 2024
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroupCarien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Frontiers in Oncology|June 1, 2022
Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian CancerWenyu Wang, Untack Cho, Anna Yoo, et al.
Gynecologic Oncology|January 21, 2024
Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trialSe Ik Kim, Je-Gun Joung, Yoo-Na Kim, et al.
BMJ Open|July 6, 2026
Impact of fertility preservation on quality of life, recurrence and reproductive success in young female cancer survivors: a Korean prospective multicentre cohort study protocol (LIFE-Repro)Hyun-Woong Cho, Se Ik Kim, Jeong-Yeol Park, et al.
The Journal of Obstetrics and Gynaecology Research|December 10, 2019
Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter studySe Ik Kim, Chel Hun Choi, Kidong Kim, et al.
Gynecologic Oncology|January 11, 2026
Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/ SHAPE trialSe Ik Kim, Jae-Weon Kim, Janice S Kwon, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapyAngelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, et al.
Cancers|August 7, 2021
Cancer Patients' Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in KoreaJune Young Chun, Se Ik Kim, Eun Young Park, et al.
Journal of Gynecologic Oncology|February 8, 2024
Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancerSeung-Hyuk Shim, Jung-Yun Lee, Yoo-Young Lee, et al.
Cancers|July 24, 2021
Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian CancerChae Young Han, David A Patten, Se Ik Kim, et al.
The Lancet. Oncology|August 30, 2024
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroupCarien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, et al.
Pageof 14